Efficacy and safety of ruxolitinib for graft-versus-host disease prophylaxis in patients with aplastic anemia undergoing PBSC-only allogeneic stem cell transplantation: a prospective phase II study.

Consistent with these findings, the ruxolitinib group also showed a trend toward reduced incidence of cGVHD compared with controls (HR 0.46, 95% CI 0.14–1.48; weighted log-rank p = 0.221; Fig. 2 C).

also in 33,237 other papers

Among other high-risk categories, including older patients (≥ 50 years; HR 0.25, 95% CI 0.02–3.74; p = 0.289), those with prior ATG exposure (HR 0.46, 95% CI 0.06–3.36; p = 0.489), and ABO-incompatible recipients (HR, 0.64, 95% CI 0.13–3.03; p = 0.510), a favorable trend was observed, though without statistical significance.

also in 993 other papers